Introduction: The incidence of oesophageal adenocarcinoma (OAC) has increased dramatically over recent years and Barrett's oesophagus (BO) is the most established risk factor for its development. Endoscopic surveillance of BO has been widely advocated but hinges on assessment of repeated endoscopic biopsies, which is problematic. The use of biomarkers presents an opportunity to reduce sampling bias and improve our ability to risk-stratify these patients.
We evaluated three novel biomarkers namely P504S, CD133 and Twist, in the setting of BO, low grade dysplasia (LGD) and OAC.
Materials and Methods: After ethical approval, the biomarkers were immunostained on an automated Ventana immunostainer. The archived biopsy materials were assessed for biomarkers expression by two independent observers using a QScore method. 25 cases each of BO, LGD and OAC were included along-with 25 cases of oesophagectomy for OAC. Any inter-observer score discrepancy of ≥ 2 was settled at a case meeting.
Results: P504S did not express in BO. Its expression was significant in cases of LGD (56%), OAC (40%) and resections (60%). CD133 also did not express in BO or LGD. It was up-regulated in cases of OAC (24%) and resections (68%). Twist expression was weak in BO and LGD. However, It was significantly over-expressed in cases of OAC (56%).
Discussion: This cross sectional study has shown increased expression of P504S, CD133 and Twist in the metaplasia-dysplasia-adenocarcinoma sequence and has suggested their possible role as potential biomarkers of Barrett's progression. Further longitudinal and prospective studies are required to validate these results.